Europe Organ-on-Chip Market

Europe Organ-on-Chip Market Size (2023 to 2028)

The size of the organ-on-chip market in the European region is predicted to reach USD 111.5 million by 2028 from USD 24.55 million in 2023, growing at a CAGR of 35.35% during the forecast period.

Growing adoption and preference for personalized medicine across the European region are key factors propelling the European organ-on-chip market. Most personalized medicine developments use organ-on-chip technology for the best results. This is one of the great alternatives to animal testing, which is very costly nowadays. People diagnosed with cancer are using personalized medicine for effective results in treatment. The development of personalized medicine also takes several clinical trials. This research can use organs on the chip to reflect individual physiology by including blood samples, primary human tissues, and induced pluripotent stem cells. For personalized, they can customize the cell culture based on the health data.

Increasing drug development and screening activities in Europe further boosts the organ-on-chip market in this region. Developing a drug is an extensive procedure that includes time and investment. The lack of human-relevant models for testing and the high failure rate in clinics raise drug development costs. Post to the drug development process, the testing process will be initiated, and several clinical trials will be done. In this case, organ-on-chip technology tests the drug by in-vitro human micro-physiological systems that can recapitulate organ-level and even organism-level functions. Human Organ-on-a-Chip can be a powerful tool for assessing drug toxicity before the drug is approved for use in clinical trials. As a result, drug development depends on organ-on-a-Chip products, which is a great way to discover drugs.

A growing number of technological advancements and increasing demand for organ-on-chips favor European market growth. Most of the researchers are focusing on implementing the organ on chip technology in different filed in the healthcare system. The developments in 3D bioprinting and 3D microfabrication help in tissue modeling and preparation of organ-like structures that are used for the growth of organ-on-chip technologies, with a wide range of applications, such as micro-robotics, drug delivery, and therapeutics help improve the growth for the market.

However, the high cost of the procedure for developing the product in pharmaceutical, different chip designs per organ, the connection between each organ to another, and avoiding infection risk at connection points are restraining the market growth.

This research report on the European organ-on-chip market has been segmented and sub-segmented into the following categories.

By Type:

• Heart-on-chip
• Human-on-chip
• Intestine-on-chip
• Kidney-on-chip
• Liver-on-chip
• Lung-on-chip

By Application:

• Drug Discovery
• Toxicology Research
• Other Applications

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, the European region accounted for a considerable share of the global market in 2022. Increasing use of organ-on-chip devices, chronic disease, and healthcare spending are the factors driving the European region's market. The European region has increased training centers for young researchers on organ-on-chip technology for career growth. The research on some of the organ-on-chip devices of the liver, kidney, retina, and heart in these training centers The European community has gathered to work on Organ-on-Chip technology. As a result, most European players are strengthened in this sector to develop advanced devices.

In addition, different programs have been launched in recent years to make awareness about organ-on-chip technology and the use of this technology by different research procedures in the healthcare sector. Cardiovascular diseases are major chronic diseases affecting many people. Nearly 4 million people die in European every year due to heart-related problems. Due to the increase in people with different types of heart diseases, drug discovery and development have increased in recent years in this region. Additionally, the shortage of donor organs drives the market forward in this region.

The UK organ-on-chip market had the major share of the European market in 2022. In recent years U.K. government has established the UK Organ-on-a-Chip Technologies Network, which is used for scientists, industrialists, clinicians, funders, and regulators working in organ-on-a-chip technology. These researchers are developing different types of drugs by overcoming the challenges facing drug development.

KEY MARKET PARTICIPANTS:

Companies playing a promising role in the European organ-on-chip market profiled in this report are Emulate, C.N. Bio Innovations, Tara Biosystems, Draper Laboratory, Mimetas, TissUse, Hesperos, Nortis, Micronit Microtechnologies B.V., Kirkstall, Cherry Biotech SAS, and Else Kooi Laboratory.